I-Mab Biopharma (IMAB) stock price, revenue, and financials

I-Mab Biopharma market cap is $1.5 b, and annual revenue was ¥30 m in FY 2019

$1.5 B

IMAB Mkt cap, 03-Jun-2020

¥30 M

I-Mab Biopharma Revenue FY, 2019
I-Mab Biopharma Net income (FY, 2019)-1.5 B
I-Mab Biopharma EBIT (FY, 2019)-210.4 M
I-Mab Biopharma Cash, 31-Dec-2019163.4 M
I-Mab Biopharma EV1.4 B

I-Mab Biopharma Income Statement

Annual

CNYFY, 2017FY, 2018FY, 2019

Revenue

11.6m53.8m30.0m

Revenue growth, %

365%

R&D expense

267.1m426.0m

General and administrative expense

25.4m66.4m

Operating expense total

292.5m492.4m

EBIT

(281.0m)(438.6m)(210.4m)

EBIT margin, %

(2431%)(816%)(701%)

Interest expense

5.6m11.7m

Interest income

858.0k4.6m30.6m

Pre tax profit

(298.2m)(401.1m)(1.5b)

Income tax expense

1.7m

Net Income

(298.2m)(402.8m)(1.5b)

Half Year

CNYH1, 2018H1, 2019

Revenue

21.4m15.0m

R&D expense

202.7m265.1m

General and administrative expense

18.7m574.6m

Operating expense total

221.4m839.7m

EBIT

(200.0m)(824.7m)

EBIT margin, %

(936%)(5498%)

Interest expense

9.1m1.9m

Interest income

980.0k12.8m

Pre tax profit

(166.7m)(857.3m)

Net Income

(166.7m)(857.3m)

I-Mab Biopharma Balance Sheet

Annual

CNYFY, 2017FY, 2018FY, 2019

Cash

307.9m1.6b163.4m

Prepaid Expenses

19.5m

Current Assets

691.6m2.0b195.5m

PP&E

22.3m27.7m30.1m

Goodwill

162.6m162.6m23.4m

Total Assets

1.0b2.4b1.7b

Accounts Payable

273.6m

Short-term debt

99.0m80.0m51.0m

Current Liabilities

195.1m346.2m588.5m

Long-term debt

114.0m67.0m17.3m

Total Debt

213.0m147.0m68.3m

Total Liabilities

309.2m415.7m668.1m

Common Stock

6.0k6.0k6.0k

Preferred Stock

445.9m

Additional Paid-in Capital

52.4m55.9m

Retained Earnings

(357.9m)(1.0b)(2.5b)

Total Equity

(299.8m)(955.1m)(2.0b)

Debt to Equity Ratio

-0.7 x-0.2 x

Debt to Assets Ratio

0.2 x0.1 x

Financial Leverage

-3.4 x-2.5 x-0.9 x

Half Year

CNYH1, 2019

Cash

1.3b

Current Assets

1.6b

PP&E

25.1m

Goodwill

162.6m

Total Assets

2.0b

Short-term debt

55.5k

Current Liabilities

413.4m

Long-term debt

73.7m

Total Debt

73.7m

Total Liabilities

491.0m

Common Stock

6.0k

Additional Paid-in Capital

366.4m

Retained Earnings

(1.9b)

Total Equity

(1.5b)

Financial Leverage

-1.3 x

I-Mab Biopharma Cash Flow

Annual

CNYFY, 2017FY, 2018FY, 2019

Net Income

(298.2m)(402.8m)(1.5b)

Depreciation and Amortization

1.6m6.7m9.8m

Accounts Payable

188.4m

Cash From Operating Activities

(252.2m)(280.7m)(868.0m)

Purchases of PP&E

(20.3m)(14.4m)(12.2m)

Cash From Investing Activities

(157.7m)9.5m30.5m

Short-term Borrowings

(11.5m)

Long-term Borrowings

(99.0m)

Cash From Financing Activities

758.6m1.5b152.7m

Net Change in Cash

348.6m1.3b(487.6m)

Interest Paid

1.7m4.9m3.0m

Half Year

CNYH1, 2018H1, 2019

Net Income

(166.7m)(857.3m)

Depreciation and Amortization

1.4m4.5m

Cash From Operating Activities

(63.7m)(389.0m)

Purchases of PP&E

(4.1m)(1.9m)

Cash From Investing Activities

14.4m158.1m

Long-term Borrowings

(80.0m)

Cash From Financing Activities

150.1m(30.0m)

Net Change in Cash

92.1m(264.1m)

Interest Paid

2.4m1.9m

I-Mab Biopharma Ratios

CNYY, 2019

EV/EBIT

-6.6 x

EV/CFO

-1.6 x

Revenue/Employee

170.5k

Financial Leverage

-0.9 x

I-Mab Biopharma Operating Metrics

Q3, 2019

Clinical and Pre-Clinical Stage Assets Developed

10

Partners

10

Patents Issued

5

Patents Pending

156